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ess: piromich@nbp.pl.Summary Lung cancer is the most common cause of cancer death in the world. It
continues to have an enormous impact on health systems of all countries. The
number of new cases is increasing in a rate of about 3% annually. Despite the
advances in the detection and treatment of lung cancer, the overall 5-year survival
still remains grim. Cigarette smoking remains the major risk factor on the incidence
of cancer, with 90% of all lung cancers occurring in smokers. The frequency of
different types of lung cancer is changing. Adenocarcinoma has become the most
frequent histologic type (50%) while squamous, previously the most common,
accounts for approximately one third of lung cancers, and small cell cancer for 15%.
Prognosis is inﬂuenced by the stage of the disease at diagnosis and by the treatment.
Screening trials that have begun in the early 1950s based on chest X-ray and sputum
cytology did not produce improvement in overall mortality. Reﬁnements in the
staging classiﬁcation of lung cancer and advances in stage identiﬁcation were
introduced in the 1990s. Post surgical mortality has declined since the 1950s but the
5-year survival rates have improved only minimally. A gradual improvement is seen in
locally advanced inoperable non-small cell lung cancer, mainly due to addition of
advanced chemotherapy and radical radiotherapy. Chemotherapy offers small
improvement for patients with NSCLC. The management of small cell lung cancer,
which appeared so promising in the 1970s has hit a plateau with vary little advance
in the last years. The biological active agents currently in phase III trails offer some
hope in the advance of therapy of lung cancer. The most important and cost-
effective management for lung cancer is smoking cessation, but for those with this
disease novel methods of treatment are urgently needed.
& 2006 Elsevier Ltd. All rights reserved.
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Introduction
In a review published in the British Journal of
Tuberculosis the author stated about lung cancer1:
R
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23124.‘‘There is no disease the people fear so much, and
no disease that is so badly neglectedy’’. This
statement is still valid. During the past 100 years,
primary carcinoma of the lung has increased in
incidence from an obscure and rarely encountered
lesion to one, which is responsible for the most
cancer deaths. Since the 16th century, it has beened.
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Erecognized that mineworkers of Germany were
known to contract serious pulmonary disorders.
The illness usually began with chronic cough,
dyspnea, and chest pain. The disorder named by
the miners Bergkrankheit was later known to them
to be fatal. The nature of this disorder remained
obscure until the works of Weigert who in 1879 and
reported on the condition as being a malignant
tumor. At that, time approximately 34 of the
employed in the German mines succumbed to
carcinoma of the lung. Between 1876 and 1938,
60–80% of all miners died from this disease. As a
result, lung cancer in miners was recognized as an
occupational disease. Various etiological factors
were believed to be the cause of this—silver,
arsenic, nickel, cobalt, and bismuth. Only in the
1920s was it shown that the most probable
etiological factor for this high incidence of cancer
in the miners was inhalation of radon gas, levels of
which were particularly high in German and Czech
mines of the Schneeberg and Joachimsthal regions.
Over 100 years ago, lung malignancy was ex-
tremely rare, accounting for only 1% of all cancers
seen at autopsy. By 1918, the percentage had risen
tenfold and in the 1920s by 14 fold.2 Alton Ochsner
recalled in his paper that the ﬁrst case of lung
cancer he saw was in 1910, witnessing an autopsy of
a patients with this disease. Only 17 years later was
he able to see another case. Within the next couple
of months he saw another eight cases and this he
termed an epidemic. All of the patients smoked
heavily.3
In the 1930s, it was noted that incidence of
malignant lung tumors have begin to increase at
the turn of the century, even more so after the First
World War. It was noted that most occurred in
males, but a steady increase was also seen in
females. Duration of the disease from being
discovered until the patient’s death was approxi-
mately 2 years, and in most, a history of chronic
bronchitis was present. What caused such an
increase in a disease so obscure? The etiologic
factors were discussed by many, most stressed the
increase of air pollution caused by the growing
industry, increase of automobile trafﬁc, exposure
to toxic gas during the World War I, the inﬂuenza
pandemic of 1918, and working with organic
sollutants.
This increase was ﬁnally admitted to be largely
due to largely spread cigarette smoking 4,5. Suspi-
cion that tobacco consumption could cause cancer
was ﬁrst acknowledged in 1761 when John Hill
reported the occurrence of polyps in snuff takers.
Two of his cases had evidence of malignancy.6 The
link between lung cancer and smoking was sus-
pected in the 1930s. Finally a case controlled study
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which a statement was made that tobacco smoking
was the single most important cause of the rising
incidence of lung cancer.2
The First World War helped to popularize the
habit of smoking. Even War heroes popularized this
addiction by stating, ‘‘You ask what it is we need to
win this war. I answer tobacco as much as
bullets’’—General John J. (‘‘Black Jack’’) Pershing.
In the following years, smoking was ‘‘appreciated’’
by thousands, until the year 1964 and the publica-
tion of the ﬁrst report on hazardous effects of
smoking and rising incidence of lung cancer by the
Surgeon General.
As stated lung cancer is mainly linked with
tobacco smoking and occupational and environmen-
tal exposure to carcinogenic agents. Other factors
have also been related to the development of lung
cancer-familial predisposition, genetic alteration,
and recently Helicobacter pylori infection.7
D
Epidemiology
An important breakthrough in understanding the
etiology of lung cancer and appreciating its
association with tobacco smoking was the paper
by Richard Doll and Austin Hill conﬁrming the
suspicion that lung cancer was associated with
smoking.8 One must keep in mind that this paper
was published when the consumption of tobacco
was it its highest in America and Europe. Even
physicians were advocating the use of tobacco in
various advertisements, and some medicines were
given in cigarettes (i.e. antiasthmatic drugs). The
second most important fact already mentioned,
was the publication in 1964 of the report of the
Surgeon General. Today we acknowledge that
tobacco smoking is the principal cause of lung
cancer, accounting for 90% of lung cancer deaths in
men and approximately 60% in women.9
The lung is the major site of cancer, in males it is
the most common, in females it is third to breast
and uterine cancer.10 It has been the most common
cancer in the world since 1985. The annual number
of new cases was estimated to be 12.4% of all new
cancer cases.10 The annual number of new cases
was estimated at 1.04 million in 1990 and 1.35
million in 2002. Worldwide it is the most common
cancer in males, in the European Union it accounts
for 21% of all cancer cases in males. It also accounts
for 29% of all cancer deaths, the most common
causes of cancer death being lung cancer (1.18
million deaths). The next most often cause is
stomach cancer (700,000 deaths), and liver cancer
(598,000 deaths).10
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AAlmost half of the cases occur in the developing
countries—a most disturbing fact. This is a dra-
matic change since 1980, when it was estimated
that 69% of the fatalities occurred in developed
countries.11
Lung cancer remains a lethal disease. The highest
observed 5-year survival in the world is reported in
the USA—15%. The average survival in Europe is
10%, while in the developing countries only 8.9%.10
Despite the advances in the last decade in the
detection and treatment of lung cancer, the overall
5-year survival rate still remains grim.12
The geographic patterns of lung cancer incidence
and mortality are very much inﬂuenced by the past
exposure to tobacco smoking. For the year 2000, an
estimated 85% of lung cancer in males and 47% in
females is the consequence of tobacco smoking.
The increase of lung cancer cases is high. World-
wide the number of cases has increased by 51%
since 1985 (44%—males, 76%—females), in males,
this increase is due to aging and growth of the
population. We estimate that the peak of the lung
cancer epidemic has passed in USA, Western and
Northern Europe.9 Incidence is increasing in South-
ern and Eastern Europe.13 In women, the epidemic
is less advanced, incidence rates are still growing as
well as mortality rates. It seams that the peak of
risk in females still has not been reached.9,14
The frequency of different types of lung cancer is
changing. Adenocarcinoma has become the most
frequent histologic type (50%) while squamous,
previously the most common, accounts for approxi-
mately one third of lung cancers, and small cell
cancer for 15%.15
As early as 1843 a statement still valid has been
published: ‘‘it is important for the practitioner to
be aware that cancer of the lung is far from being
affectation of such uncommon occurrence as is
generally supposed’’.16 Lack of helpful auscultatory
signs did not help in diagnosis of this disease in the
early 19th century. Laennec (in 1834) knew that
presence of auscultatory signs meant that the
tumor has grown considerably in the lung.16 In
1881, Fraser stated that ‘‘the existence of lung
cancer may be clearly indicated by the physical
signs and symptoms’’.16 As far as early 19th century
the diagnosis of lung cancer proved to be difﬁcult,
mainly due to the rarity of the disease, and it
remains so today despite the fact the disease
incidence has evolved to epidemic size.
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In order to decrease the gruesome statistics of lung
malignancy two major efforts to screen for lungcancer have been conceived. The ﬁrst program was
based on routine chest radiograms the second,
which is still ongoing uses low dose-computed
tomography. The results of randomized studies
using chest radiograms failed to show a reduction
in mortality due to lung cancer.17–19 These studies
have been criticized for being underpowered and
having high contamination ratios in the control
arms. A study (planed for 10 years) sponsored by
the National Cancer Institute has been started but
the results of it will be available in the future. This
study is constructed to determine the effect of
chest radiograms in reducing by 10% the mortality
due to lung cancer. It will compare one arm of
smokers screened with chest radiograms versus the
arm of smokers not screened with chest radio-
grams. Summarizing, current evidence does sup-
port screening for lung cancer with routine chest
radiograms or sputum cytology.20 Further questions
should be answered. Presently it is impossible to
accurately distinguish those 16% of males and 7% of
female life long smokers who will develop cancer
from their fellow smokers who will not.21 Is
screening worth doing? Yes it is because much more
resectable cases are picked up and thus more
patients are cured.21 The Mayo Lung Project high-
lighted another problem-identiﬁcation of early
lesions. Screening usually allows diagnosing periph-
eral tumors, of which most of the lesions (over 70%)
were already present on earlier radiograms, but
were missed at that time.22
Several studies have been carried out using low
dose spiral CT which is much more sensitive in
detecting pulmonary nodules in comparison to
standard chest radiograms.19,23,24 The results of
these studies will probably be available over the
next few years. Limitations now arise with baseline
granulomas (i.e. old tuberculosis, histoplasmosis,
coccidioidomycosis).
The incidence of lung cancer have stimulated
numerous research projects directed toward the
use of biological markers in screening, staging,
disease monitoring and for prognosis. Biological
screening tools are still being developed 25,26,
produced by tumor cells themselves 25,27,28, as well
as products induced by the cancer therapy 29 or
tumor invasion of the extra cellular matrix.30
One surface marker for early detection of lung
cancer is the heterogeneous nuclear ribonucleo-
protein A2/B1 that is upregulated on premalignant
bronchial epithelium. In reassessing sputum over
expression of A1/B2 was more sensitive marker of
early malignancy than normal cytologic screening.
Features of malignancy was o the average seen 1
year before the cytological examination and before
the tumor was seen on plain chest radiogram.31,32
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cancer screening programs has been debated. Some
lung cancers detected by screening may never
progress to produce symptoms or cause death in
that individual’s lifetime.33AStaging
The staging of lung cancer has undergone signiﬁ-
cant changes over the last 100 years. Today
appropriate staging is mandatory for correct
therapy. The most signiﬁcant dividing line is
between those patients that can undergo surgical
resection and those who are inoperable, but may
beneﬁt from chemo- and radiotherapy. The basis
for staging is the TNM system (tumor, nodal
involvement, distant metastasis) 34,35. Until the
1970s, the only tool for staging of lung cancer was
the plain chest radiogram. Being insensitive and
nonspeciﬁc, the extent of the malignant process
within the chest was very difﬁcult to assess.
Introduction of the CT scan allowed comparison of
this imaging method with the gold standard of
staging—mediastinoscopy and surgery. Various stu-
dies allowed to demonstrate that isolated CT
ﬁndings could not be considered evidence that
lymph nodes were malignant. It is estimated that
about 40% of all nodes deemed to be malignant, are
actually benign.36 CT scans provided too much
‘‘false positive’’ ﬁndings, and the speciﬁcity could
be affected by clinical factors such as presence of
postobstructive pneumonitis 36–38. Despite these
drawbacks CT scans remain, the most widely used
imaging test for staging of lung cancer. It is used to
evaluate the extent of the invasion of the struc-
tures by the malignant process.
One of the most important questions to answer is
whether the tumor is resectable. CT scan may
interpret proliferation of connective tissue adja-
cent to the tumor as malignant. Magnetic reso-
nance imaging (MRI) demonstrates advantages over
CT scans because of its multiplanar imaging and
large differences in intensity between tumor and
soft tissue. It is of value in assessing mediastinal
invasion allowing delineation of the mediastinal fat
plane.39
Another modality for staging lung cancer is
positron emission tomography (PET). Currently, 2-
[18F]ﬂuoro-2-deoxy-D-glucose based PET is the
most promising. The radiolabeled glucose analog
accumulates in cells that have high glucose utiliza-
tion and can be identiﬁed by the PETcamera. It can
detect malignancy in focal pulmonary lesions
greater than 1 cm with a sensitivity of 97% and
speciﬁcity of 78%.40
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TRPooled data evaluating the sensitivity and speci-
ﬁcity for staging the mediastinum were identiﬁed
combining over 4500 patients. The pooled sensitiv-
ity data for CT scanning of the mediastinum was
0.60 (95% conﬁdence interval 0.51–0.68) and the
pooled speciﬁcity was 0.81 (95% CI, 0.74 -0,89).
The pooled sensitivity of PET was 0.85 (95%CI,
0.79–0.89) and the pooled speciﬁcity was 0.88 (95%
CI, 0.82–0.92). It seems that PET has both higher
sensitivity and speciﬁcity for identifying lesions of
the mediastinum.37
Although PET has a much higher overall accuracy
than CT scanning for detecting intra- and extra-
thoracic disease, both false positive and false
negative ﬁndings can be identiﬁed. Infections,
granulomatous and collagen diseases affect false
positive ﬁndings. False negative are seen in lesions
smaller than 1 cm, in bronchioalveolar carcinoma
and carcinoids 41–43.
Tissue conﬁrmation of abnormal ﬁndings discov-
ered during any imaging procedure is the rule in
most cases. Improvements in technology have
increased the use of bronchoscopy with transbron-
chial aspiration needle biopsy and bronchoalveolar
lavage (BAL). For staging use of endoscopic ultra-
sonography with bronchoscopy, mediastinoscopy,
transthoracic needle biopsy allow minimal invasive
tissue procurement and more accurate staging
44–48. Does this mean that the age of mediastino-
scopy is over? No, mediastinoscopy remains the
golden standard with its extremely high sensitivity
and speciﬁcity coupled with low morbidity.49
Transbronchial lymph node sampling via a
bronchoﬁberscope is less invasive than mediastino-
scopy. The sensitivity of this technique is variable
(50–89% that of mediastinoscopy) but it does
increase with endobronchial ultrasound (EBUS) or
CT guiding 50–52.
Having established the respectability of the
primary tumor by the staging procedures addressed
above, a search should be started for metastatic
disease, but only if this indication does exist. The
preferred imaging techniques are CT scan of the
chest, CT or MRI with contrast of the brain and a
technetium bone scan. The use of whole body PET
scan is still evolving but one should be aware that
this technique can identify noncerebral metastatic
disease not detected by standard imaging techni-
ques in up to 20% of the cases.53
The presence of metastasis in non-small cell lung
cancer (NSCLC) depends on the extent of the
intrathoracic involvement. The larger and more
biologically aggressive the tumor and nodal invol-
vement, the greater the likelihood of metastatic
disease. In Stage I disease only 1% of the patients
demonstrate metastases.54 Nevertheless it was
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NSCLC had evidence of distant metastasis without
any clinical signs of distant involvement 55–57. The
most affected organs being: brain, bone, liver, and
adrenal glands. It is now a standard to include
examination of the adrenals and liver as part of the
staging CT of the chest and upper abdomen 58,59.ASurgery
In the 1970s, the most successful means of
management of carcinoma of the lung was surgical
removal. The ﬁrst successful one stage pneumo-
nectomy for carcinoma of the lung was performed
by Graham in 1933.60 The patient survived this
procedure and went on to practice medicine. After
this report was made known the world was
convinced that lung cancer is a curable disease.
Actually, the ﬁrst deliberate attempt at pulmonary
resection was performed in 1821 when Anthony
Milton removed ‘‘one or two pounds of pulmonary
tissue’’ along with two portions of ribs. The
patients survived the immediate postoperative
period and died 1 year later.
As surgery became more feasible, it became
quite clear that the majority of the patients at the
diagnosis were not suitable for resection, mainly
due to dissemination of the disease. Even if they
were technically suitable for surgery the procedure
in many of these patients represented too much of
a risk. The reason being-concominant disease
(particularly heart disease), and the prospect of
removing a lung and deterioration of the lung
function that would follow this. In the late 1960s, it
was realized that the following are adverse prog-
nostic factors: weight loss of more than 4.5 kg,
physical evidence of cancer, pneumonectomy, ob-
struction of a main bronchus, blood vessel invasion
by the tumor, involvement of the lymph nodes
(hilar and/or mediastinal), while the following
could be beneﬁcial for the patient-age under 60
years, procedure carried out o the right lung, and
tumor conﬁned to one lung.61
For the following years another factor emerged-
whether to operate patients older than 70 years.
This was a crucial questions, mainly because it
affected more than half of the population of
patients with cancer.62 The efforts to reduce
mortality due to surgical procedures did succeed.
Data in the 1960s and 1970s showed that 3–17%
patients died during 30 days after surgery. Still
emphasis was made on careful selection of patients
and carrying out lung sparing procedures whenever
possible.63
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TRAs previously stated the most important devel-
opment in surgery of lung cancer was introduction
of modern staging. Parrot who pointed out that
changes in the hilar lymph nodes could reﬂect
diseases of the lung already stressed importance of
the hilar lymph nodes in 1876. In 1949, Daniels
reported that lymph nodes on the scalene fat pads
often showed the same pathology as suspected in
the lungs and that biopsy of these nodes could
poses diagnostic value. Poor results of the Daniels’s
biopsy resulted in the introduction of exploration of
the upper neck and mediastinal lymph nodes
whenever possible. This diagnostic method did
have its drawbacks especially when it became
apparent that lung cancer could produce contral-
ateral spread. In 1959, Carlens devised modern
mediastinoscopy.64 This enormously helped to
approach any pathological structures of the med-
iastinum. Finally in 1974, a modern classiﬁcation of
tumor extent and the TNM classiﬁcation was
applied to lung cancer.65
Today for NSCLC surgical resection remains the
primary modality to consider in any therapeutic
approach. However, as patients become older,
attempts to safely resect tumors in this subpopula-
tion, have led to development of lung conserving
procedures. The ﬁrst lung conserving procedure
was wedge resection, which was already performed
in the early 1970s 66,67. Initially these wedge
resections did appear attractive unfortunately both
retrospective and prospective studies show a higher
recurrence rate and worse survival in patients
undergoing wedge resection.68 Nevertheless it still
offers these high-risk patients the possibility for
cure.
Introduction of the CT scan allowed earlier
diagnosis of smaller tumors, thus earlier and
limited surgery became more feasible. This limited
approach included video thoracoscopic surgery for
wedge resection and even lobectomy for smaller
tumors. The latter does provide only limited
intrathoracic nodal sampling thus making full
staging controversial, but it is associated with less
preoperative morbidity, better pain control and
ultimately shorter hospitalization periods.
The 5-year survival for pneumonectomy remains
at a low 40%; it also carries higher perioperative
mortality in comparison with lobectomy. Efforts to
improve the cure rates following modern staging
and surgical procedures include neo and adjuvant
chemotherapy, pre- and postoperative radiother-
apy. Only a limited number of prospective
studies are available that assess the role of
neoadjuvant chemotherapy. Two small trials are in
favor, whereas a trial on a larger population
failed to conform the advantage of neoadjuvant
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tested in randomized controlled trials. The results
can affect the role of modern neoadjuvant therapy
in lung cancer treatment.
In contrast to neoadjuvant therapy, more success
has been demonstrated in the role of adjuvant
chemotherapy. In 1995 and later, large meta-
analyses of randomized controlled trials demon-
strated that adjuvant chemotherapy offers an
approximately 5% advantage over surgery alone
72–75. This improvement in longer survival with
adjuvant therapy is better than seen in other solid
tissue tumors. Thus, patients will be asked to
consider postoperative chemotherapy after a cura-
tive resection, as a further 5% survival advantage is
very important.A
Radiotherapy
Few advances in radiotherapy have been made to
improve the survival of patients with lung cancer;
in fact as a curative modality, it has been
disappointing. Despite trials with escalating doses
up to 80Gy, radiotherapy demonstrated only a 5
year survival rate of 7–10% 76,77. Patients that
either refuse surgery or are not medically ﬁt, but
their cancer is resectable can be considered for
radical radiotherapy. Is this method comparable
with surgery? Only one study addressed this issue.78
Fifty-eight patients were randomized to resection
or radical radiotherapy. Survival (4-year period)
was for surgery 23% and 7% for those receiving only
radiotherapy. This study and various nonrando-
mized ones have serious drawbacks. Usually only
one clinical stage is assessed, groups vary in staging
procedures, comorbid diseases are present, etc.
The best results can be seen in tumors of a
diameter less than 4 cm. The complete response
ranges from 48% to 52%. Overall 5 year survival
periods vary in these studies from 6% to 32% 78,79.
Important for prognosis is the tumor size and
radiation dose. Age and histogic type has no effect
has on survival. We still lack studies that utilize
modern treatment with CT planning and conformal
treatment, in which the shape of the radiation is
molded to the tumor.
Presently radiotherapy is used as a postoperative
measure as a standard therapy after surgical
resection of the N2 disease. Use of moderate doses
to eradicate residual disease with have been
established.80
The role of radiotherapy in Stage III disease is
difﬁcult to assess. When part of a multimodal
treatment, should radiotherapy be, concurrent
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TRwith chemotherapy or sequential? Does the manner
of dose administration (daily versus accelerated)
matter? These questions are especially valid for the
Stages IIIA and IIIB patients. The group of Stage III
patients is heterogeneous. Without mediastinal
staging it is not possible to distinguish between
the two groups. This does not effect the outcome in
both groups thus both can be assessed together.80
Comprising probably as much as 30% of the new
cases of NSCLC patients. In general, the 5-year
survival does not exceed 5%. Prognosis following
radical radiotherapy is inﬂuenced by the initial
tumor size and nodal status. The median survival
time does not exceed 12 months, ranging from 2 to
12 months 81,82. Better survival is reported for
higher doses, the 3 years survival was 6% with 40Gy,
10% with 50Gy, and 15% with 60Gy.83 The effect of
dose intensiﬁcation using three dimensional con-
formal radiotherapy should be further evaluated.84
Radiotherapy is also used as a palliative measure
to relieve local symptoms of lung cancer. Improve-
ment in intensity of symptoms such as chest pain,
cough and breathlessness in more than 50% of the
cases has been shown 85–87. Few studies have
addressed the question of palliative radiotherapy
on survival. Most studies have shown that irrelevant
of the dose the effect was approximately the same.
Only the most recent MRC study compared two
fractions on patients with good performance
status. The study conﬁrmed good palliation with
two fraction regimen and a small survival advan-
tage for the higher dose regimen (3% at 2 years).85
Use of higher doses of radiotherapy has its
disadvantages, thus the use of doses directed to
the airway (endobronchial radiotherapy) from its
lumen is particularly useful in those patients that
have received close to maximum dose of external
beam radiotherapy. Radical radiotherapy can also
be delivered this way especially in cases with the
tumor localized within or very close to the airway
lumen. Endobronchial radiotherapy has a long
history of usage. Radium needles and cobalt pearls
were used to destroy tumors of the upper airways.
The standard mode of local brachytherapy uses
iridium placed in the airway through a bronchoﬁ-
berscope. The dose depends on the aim of the
therapy—for palliation a dose of 10–15Gy in 10mm
is used, 20–25Gy if cure is intended. The response
occurs within 10–20 days. Brachytherapy can be
used for endobronchial clearance. Its use with laser
endotherapy gives an additional symptoms free
period in comparison with the use of laser alone.88
For palliation it is a remarkable tool.89
In small cell lung cancer (SCLC) radiotherapy was
examined as a means to control locally the primary
tumor site, especially in cases of complete or
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radiotherapy after partial or complete response to
chemotherapy was assessed in several meta-ana-
lyses of randomized controlled trials. These ana-
lyses did show an improvement but only a modest
one. Perhaps the reason for this being that two
groups of trials are available, one looking at a 2
year survival period, the other at a 3 years survival
period.90,91 At 3 years, 9% of the patients who
received chemotherapy alone and 14% of those who
received combined treatment (chemo- and radio-
therapy) were alive. In addition, a 14% reduction in
the risk of death for the combined modality was
seen. This enabled to introduce radiotherapy in the
treatment of SCLC patients that responded to
chemotherapy on a standard basis. Further studies
were needed to place the timing of radiotherapy in
these patients. Several studies showed a beneﬁt
following early radiotherapy whereas other did
not.92–95 Nevertheless the message is quite clear
hyperfractionated radiotherapy given early is more
effective than single daily fractionation schedules,
given early or late.96 The other message from these
studies is to deliver the optimal chemotherapeutic
regimen (including selection of agents and inten-
sity). Failure to do so limits the potential beneﬁt of
radiotherapy in SCLC patients. AChemotherapy
Surgical resection or radical radiotherapy as shown
previously may cure only 10% of all patients with
NSCLC. The vast majority will present or develop
advanced disease and ultimately die. The natural
history of advanced NSCLC is particularly poor. The
median survival being 4–6 months. Chemotherapy
may be a logical approach but currently no
evidence is present that chemotherapy can cure
NSCLC patients.20 Early trials with chemotherapy
demonstrated a response rate of 10–15%. This was
quite disappointing especially that the response
rate for SCLC was approximately 50%. There is
evidence that chemotherapy in NSCLC can palliate
and prolong life in some patients. The gain over
best supportive care was more than 5 weeks, with
only a 10% improvement in survival at 1 year.97 The
real advantage was observed only in patients
receiving cis-platin containing regimens. Use long
acting alkylating agents (cyclophosphamide, meth-
otrexate, and vinblastine) was associated with
worse results than best supportive care alone. Over
the last years, newer agents have emerged provid-
ing better median and 1-year survival. Unfortu-
nately the effect of these agents is minimal, the
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only 35–40% were alive at 1 year.98,99 Although the
results of these newer regimens are not that
exciting, they do offer one major advantage.
Modern chemotherapy with carbo- or cis-platin
and vonorebine, taxane, or gemcitabine can be
administered earlier on an outpatients basis,
producing less side effects (nausea, loss of hair,
vomiting), improving the quality of life of the
patients. This may outweigh the side effects of
chemotherapy itself.20,100 Is this cost effective? The
other costs of chemotherapy-toxicity, potential
detriment of quality of life, are questions that are
even more important. The answers to which are
now only emerging.
Many of the published trials are biased. Most are
conducted in patients with better performance
status and younger individuals. The results are then
applied to patients with advanced NSCLC. Despite
that lung cancer is increasing in older patients, less
than 20% of patients over 70 years of age are
recruited in such trials. Most of the recruited
patients also exhibit good performance status,
whereas in reality most of the patients present
much lower performance status. There is much to
be done, trials should be carried out in older
patients, especially that there is evidence that
good-performance-status elderly patients respond
just as well as younger individuals 101.
New approach to treatment is emerging from
targeted therapy. Identiﬁcation in NSCLC of muta-
tions in the epidermal growth factor receptor
(EGFR) has made it an attractive target for various
antitumor regimens. Aberrant signaling from EGFR
is known to be important in the development and
progression of NSCLC. Oral inhibitors of EGFR
(geﬁtinib, erlotinib) selectively inhibit the intra-
cellular tyrosine kinase activity of the EGFR. Both
have demonstrated antitumor activity in patients
with advanced NSCLC who had relapses after
convention chemotherapy. Unfortunately despite
common expression of EGFR in NSCLC responses to
these agents are few, limited to women, nonsmo-
kers, and those with bronchoalveolar carcino-
ma.102–106 Other EGFR tyrosine kinase inhibitor
are under investigation-cetuximab, as well as the
antiangiogenic vascular endothelial growth factor
monoclonal antibody bevacizumab.107–109 Studies
assessing the role of thalidomide another angio-
genic substance are currently carried out in both
NSCLC and SCLS.110,111 The results of these studies
are very much needed.
Chemotherapy has been evaluated as neoadju-
vant and adjuvant therapy around surgery, around
radiotherapy and as primary treatment for ad-
vanced inoperable disease.
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AThe place for chemotherapy before surgery has
been controversial for the past 15 years. The most
important being—what is the role of neoadjuvant
chemotherapy in resectable patients (Stage I or II
disease, limited Stage IIIA) and can it debulk the
more advanced disease. The studies addressing
these questions give conﬂicting results. These
studies cannot be compared. The chemotherapy
regimens varied, administration of radiotherapy
also varied, it was given pre-, intra- and post-
operatively.69–71,112
SCLC remains the most frustrating cancer. In the
1970s, randomized trials brought some optimism
concerning SCLC treatment as new molecules were
discovered, and soon use of them especially in
combination produced much awaited progress in
chemotherapy. Objective responses were seen in
the majority of patients, the median survival
rapidly rose from the 5 months observed in
untreated patients to 18–20 months for those with
limited disease and from weeks to 6–9 months with
extensive disease.113 Criteria identiﬁed those most
likely to live 2 years and those to die quickly.113–115
The most independent prognostic factors being:
disease extent, performance status, serum alkaline
phosphatase, plasma albumin, and sodium concen-
tration. These simple serum analyses and the
patient’s performance status gives much more
information than disease extent assessed with the
most sophisticated and expensive imaging systems.
This is very helpful from the practicing physicians
point of view.
Toxicity following chemotherapy is a factor that
can be dose limiting in these patients and its
magnitude although generally predictable can be a
major problem. Baring in mind that regimes tend to
increase the doses of chemotherapy (to improve
response rates and median survival), toxicity can
be a limiting factor in such regimens. Certain
patients carry a particularly high risk of death after
the ﬁrst chemotherapy cycle. These are patients
with hepatomegaly, low plasma albumin, high
alkaline phosphatase and poor performance sta-
tus.116
Unfortunately, little progress has been observed
lately. Better-tolerated new agents (etoposide,
carboplatin) have been introduced. Survival was
extended by introducing radiotherapy to the
mediastinum. Prevention of high morbidity cerebral
relapse was achieved by prophylactic whole brain
radiotherapy.117 Intensiﬁcation of chemotherapy
with bone marrow or granulocyte-macrophage
colony-stimulating factor support have all failed
to signiﬁcantly improve the prognosis.118,119 Pa-
tients continue to beneﬁt from treatment mainly
due to the high response rate and signiﬁcant quality
RE
Rof life improvement but second line chemotherapy
has a disappointing effect, manifesting few re-
sponses, and short progression-free intervals120–122.Detection of early lung cancer
Early detection of lung cancer lesions is needed if
progress in treating this disease should become a
reality. The World Health Organization recognizes
three main forms of preinvasive lesions in the lung:
(1) squamous dysplasia/carcinoma in situ (SD/CIS);
(2) atypical adenomatous hyperplasia (AAH); and
(3) diffuse idiopathic pulmonary neuroendocrine
cell hyperplasia (DIPNECH).123 Little is known about
the biology of these lesions, although is it thought
that squamous cell cancer rises from SD/CIS
lesions. There is evidence that AAH may progress
from low to high-grade lesions and eventually to
bronchioalveolar cell carcinoma and ﬁnally periph-
eral adenocarcinoma.123 DIPNECH, a rare entity, is
thought to be associated with the development of
multiple carcinoid tumors.
Attention has been lately focused on the detec-
tion of early centrally localized SD/CIS lesions. The
development of ﬂuorescence bronchoscopy is con-
sidered to be one of the important new initiatives
in detection of early squamous cell lung cancer.
Bronchoscopy using only white light has a yield over
90% for detecting macroscopic centrally localized
lesions, it is much more inferior in detecting early
lesions, especially SD/CIS.124
It has been recognized that normal, dysplastic
and malignant cells exposed to a speciﬁc wave-
length of light will emit electromagnetic radiation
of different frequencies. Fluoroscopic broncho-
scopy takes advantage of this and allows the
experienced bronchoscopist to recognize the dif-
ferences, permitting to perform biopsies of se-
lected areas that emit the pathological light.125
These areas are thought to be the earliest
manifestations of lung cancer. Their discovery
could improve the prognosis in high-risk patients.
Unfortunately, this method is not free of false-
positive results, which are caused by suction
trauma, asthma, mucous gland hyperplasia, or
acute purulent bronchitis. The relative sensitivity
of conventional and ﬂuorescence bronchoscopy
versus white light bronchoscopy alone was 6.3 for
intraepithelial neoplastic lesions and 2.71 when
invasive carcinoma were also included. However,
only 95 out of 285 biopsies taken from areas of
abnormal light emission contained abnormal tissue,
which gave a very high false positive rate of
66%.126 The real signiﬁcance of suspicious ﬁndings
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Adiscovered with ﬂuorescence bronchoscopy is still
not known, although two cases in which pathologi-
cal light emission was observed progressed to
dysplasia and to carcinoma.127 Most of the early
studies carried out using ﬂuorescence broncho-
scopy were biased by the fact that the ﬂuorescence
bronchoscopy was always preceded by white light
examination. Although the cumulative evidence
looks favorable, it is too early for ﬂuorescence
bronchoscopy to be considered outside its role as a
research tool in the detection of early signs of lung
cancer.
Another question should also be answered. What
is the most appropriate way to manage these
intraepithelial lesions once they are discovered?
Unfortunately most studies carried out cannot
answer the question what happens if high-grade
lesions are left untreated.128
Summarizing lung cancer at the beginning of the
20th century was a disease that was not often
diagnosed and even less frequently treated. The
most noticeable advance has been the recognition
that smoking is the causal agent for this disease.
Major technical advantages especially in imaging
allow earlier diagnosis and more successful therapy,
especially sophisticated surgical procedures, mod-
ern chemo- and radiotherapy. Despite these major
advances, they have brought only minor improve-
ments in survival. Several observations of lung
tumor biology have inﬂuenced the selection of new
treatment modalities, effecting oncogenesis. This
enabled a better-deﬁned role of chemotherapy in
NSCLC.
The next decade will be one of screening trials
for early detection of disease, management of in-
situ carcinoma lesions, assessment of new biologi-
cal agents, perhaps replacing present day che-
motherapy, and above all smoking cessation.
RT
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